Phase-I Study Evaluating the Pharmacokinetic Profile of RhuDex®

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00532012
Recruitment Status : Completed
First Posted : September 19, 2007
Last Update Posted : July 16, 2008
Information provided by:

Brief Summary:

The drug that is under investigation during this study is RhuDex® and is expected to be used as an oral treatment for rheumatoid arthritis. Normal stomach juices contain acid and previous studies have shown that this acidity reduces the solubility and therefore the absorption of RhuDex®. Administering the alkaline buffer meglumine with RhuDex® has shown to increase the solubility of RhuDex® by decreasing the stomach acidity.

The purposes of this study are to determine:

  • the optimum level of meglumine which is required to achieve the best uptake of RhuDex® from the stomach into the blood
  • to determine the concentration of RhuDex® in the blood in the presence of the optimum level of meglumine
  • to investigate further the safety and tolerability of RhuDex®. The study will be conducted in healthy male volunteers.

Condition or disease Intervention/treatment Phase
Pharmacokinetics Drug: RhuDex® Phase 1

Detailed Description:
RhuDex® is a novel, orally bioavailable, low molecular weight modulator of co-stimulation of T lymphocytes. RhuDex® binds to the protein CD80 on the surface of antigen-presenting cells and inhibits its interaction with CD28 (but not with CTLA-4) presented by CD4+ T lymphocytes.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: An Open-Label, Partially Randomized, Cross-Over, Monocentric Phase I Study Evaluating the Pharmacokinetic Profile of RhuDex® in Order to Determine Optimum Doses of Meglumine and RhuDex®
Study Start Date : September 2007
Actual Primary Completion Date : October 2007
Actual Study Completion Date : November 2007

Primary Outcome Measures :
  1. Pharmacokinetic Profile

Secondary Outcome Measures :
  1. Safety Profile

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male subjects between 18 and 60 years at the time of enrollment
  • Male volunteers and their partners who are of child-bearing potential must agree to use a double-barrier method of contraception during the study and for 12 weeks after discharge
  • BMI between 18.5 and 29.9 kg/m²
  • Written informed consent
  • Ability to comply with the requirements of the study

Exclusion Criteria:

  • Acute infection at time of enrollment
  • History of chronic inflammation, chronic infection, other chronic disease, autoimmune disorders (e.g. diabetes mellitus) or cancer
  • Clinical significant abnormal ECG
  • Clinical significant abnormal laboratory values (especially in terms of liver or renal insufficiency)
  • Clinically significant physical findings
  • Major surgery within the last 4 weeks prior to enrollment
  • Organ allograft recipient
  • Concomitant or planned treatment which would interfere with study results
  • Any systemic medical treatment, including over the counter products and dietary supplements such as iodine, fluoride or vitamins, within one week before and during the study course
  • Known allergy against any ingredient of the study medication or meglumine
  • Participation in an investigational trial within 30 days prior to enrollment
  • Systemic intake of immunosuppressive or immunomodulatory medication or vaccination within 30 days prior to enrollment and for the whole study duration
  • Blood loss exceeding 450 mL (including blood donations) within 12 weeks prior to enrollment into the study
  • Medical history of alcohol or drug abuse or alcohol consumption greater than 21 units per week for males. A unit of alcohol is equivalent to: half a pint of average strength beer (280 mL), a glass (125 mL) of wine or a standard measure (25 mL) of spirits, sherry or port
  • A positive alcohol breath test
  • A positive urine drug screen
  • Regular smokers (more than 20 cigarettes or 5 cigars per day)
  • Presence of hepatitis B surface antigen (HBsAG), hepatitis C antibody (HCV Ab) or HIV-1 or HIV-2 antibodies at screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00532012

United Kingdom
Charles River Clinical Services Edinburgh Ltd
Edinburgh, United Kingdom, EH14 4AP
Sponsors and Collaborators
Principal Investigator: Stephen Freestone, MD INC Research

Responsible Party: Hoda Tawfik / Clinical Trial Manager, MediGene Identifier: NCT00532012     History of Changes
Other Study ID Numbers: CT 5001
First Posted: September 19, 2007    Key Record Dates
Last Update Posted: July 16, 2008
Last Verified: July 2008

Keywords provided by MediGene:
Rheumatoid Arthritis
Oral Bioavailability